UBS Group
MRM

UBS Group’s MEDIROM Healthcare Technologies MRM Stock Holding History

UBS Group’s Portfolio MRM Stock Details MRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28K Buy
27,181
+633
+2% +$711 ﹤0.01% 7938
2026
Q1 		$29.7K Buy
26,548
+22,932
+634% +$33.3K ﹤0.01% 7691
2025
Q4 		$7.02K Buy
+3,616
New +$7.75K ﹤0.01% 8487
2025
Q3 		– Sell
-33,280
Closed -$47.3K – 10705
2025
Q2 		$47.3K Sell
33,280
-65,004
-66% -$71.9K ﹤0.01% 7820
2025
Q1 		$36.2K Buy
98,284
+53,110
+118% +$41.9K ﹤0.01% 7824
2024
Q4 		$46.5K Buy
45,174
+27,137
+150% +$67.6K ﹤0.01% 7345
2024
Q3 		$54.1K Buy
18,037
+18,007
+60,023% +$67.3K ﹤0.01% 6768
2024
Q2 		$118 Buy
+30
New +$165 ﹤0.01% 9138
2023
Q2 		– Sell
-4
Closed -$25 – 9380
2023
Q1 		$25 Sell
4
-1,935
-100% -$11.7K ﹤0.01% 9402
2022
Q4 		$8.74K Sell
1,939
-173
-8% -$1.02K ﹤0.01% 8735
2022
Q3 		$13K Buy
2,112
+7
+0.3% +$44 ﹤0.01% 8048
2022
Q2 		$13K Sell
2,105
-9,812
-82% -$69.5K ﹤0.01% 7523
2022
Q1 		$88K Sell
11,917
-920
-7% -$6.24K ﹤0.01% 6012
2021
Q4 		$78K Buy
12,837
+12,237
+2,040% +$89.2K ﹤0.01% 6516
2021
Q3 		$5K Buy
+600
New +$4.55K ﹤0.01% 8544
2021
Q2 		– Sell
-1,835
Closed -$21K – 9643
2021
Q1 		$21K Sell
1,835
-566
-24% -$7.15K ﹤0.01% 7337
2020
Q4 		$35K Buy
+2,401
New +$35.5K ﹤0.01% 6506

Other funds holding MRM

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

UBS Group's MRM Position: Q2 2026 in Review

UBS Group increased its MEDIROM Healthcare Technologies (MRM) stake by 2.4% in Q2 2026, buying an estimated $711 and bringing the position to 27,181 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #7938.

UBS Group first reported a position in MRM in Q4 2020 and has held it in 17 quarters since. The position peaked at $88K in Q1 2022. 8 funds tracked by Wall St. Rank hold MRM as of Q2 2026.

  • UBS Group held 27,181 shares of MEDIROM Healthcare Technologies worth $28K as of Q2 2026.
  • UBS Group bought 633 MEDIROM Healthcare Technologies shares in Q2 2026, an estimated $711.
  • MEDIROM Healthcare Technologies made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7938 holding.
  • UBS Group first reported a position in MEDIROM Healthcare Technologies in Q4 2020 and has held it in 17 quarters since.
  • UBS Group's MEDIROM Healthcare Technologies position peaked at $88K in Q1 2022.
  • 8 funds tracked by Wall St. Rank held MEDIROM Healthcare Technologies as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.